Información del artículo
La hipercolesterolemia familiar es un trastorno hereditario autosómico dominante del metabolismo de las lipoproteínas, que se caracteriza por unas concentraciones plasmáticas muy altas de colesterol ligado a lipoproteínas de baja densidad, xantomas tendinosos y aumento del riesgo de enfermedad coronaria prematura.
Aunque la hipercolesterolemia familiar se puede sospechar mediante criterios clínicos y bioquímicos, el análisis genético aporta un diagnóstico de certeza y ayuda a conocer la influencia del tipo de mutación en la expresión fenotípica de la enfermedad. En la actualidad, se ha desarrollado en España un ADN-chip, o biochip, que permite un diagnóstico genético rápido y de fácil accesibilidad.
El grave riesgo cardiovascular de estos pacientes hace preciso un diagnóstico temprano que ponga en marcha las medidas preventivas con los diferentes tratamientos hipolipemiantes.
Palabras clave:
Hipercolesterolemia familiar
Criterios diagnósticos
Tratamiento hipolipemiante
Familial hypercholesterolemia (FH) is a autosomal dominant disorder of lipoprotein metabolism characterized by very high plasma concentrations of low density lipoprotein cholesterol, tendon xanthomas and increased risk of premature coronary heart disease.
Although FH can be suspected by using clinical and biochemical criteria, genetic analysis allows definitive diagnosis and helps to identify the type of mutation in the phenotypical expression of the disease. A DNA chip or biochip that allows rapid and accessible genetic diagnosis has been developed in Spain.
Because of the high cardiovascular risk in these patients, early diagnosis is essential to start preventives measures with various lipid-lowering therapies.
Key words:
Familial hypercholesterolemia
Diagnostic criteria
Lipid-lowering therapy
El Texto completo está disponible en PDF
Bibliografía
[1.]
J.L. Goldstein, H.H. Hobbs, M.S. Brown.
Familial hypercholesterolemia.
pp. 2863-2913
[2.]
H. Mabuchi, S. Miyamoto, K. Ueda, M. Oota, T. Takegoshi, T. Wakasugi, et al.
Causes of death in patients with familial hypercholesterolemia.
Atherosclerosis, 61 (1986), pp. 1-6
[3.]
T. Miettinen, H. Gylling.
Mortality and cholesterol metabolism in familial hypercholesterolemia.
Atherosclerosis, 8 (1988), pp. 163-167
[4.]
F. Civeira.
Guidelines for the diagnosis and manegement of heterozygous familial hypercholesterolemia.
Atherosclerosis, 173 (2004), pp. 55-68
[5.]
M.A. Austin, C.M. Hutter, R.L. Zimmern, S.E. Humphries.
Genetic causes of monogenic heterozygous familial hypercholesterolemia: a HuGE Prevalence Review.
Am J Epidemiol, 160 (2004), pp. 407-420
[6.]
M.S. Brown, J.L. Goldstein.
A receptor-mediated pathway for cholesterol homeostasis.
Science, 232 (1986), pp. 34-47
[7.]
A. Cenarro, H.K. Jensen, F. Civeira, E. Casao, J. Ferrando, J. González-Bonillo, et al.
Two novels mutations in the LDL receptor gene: common causes of familial hypercholesterolemia in a Spanish population.
Clin Genet, 49 (1996), pp. 180-185
[8.]
A. Cenarro, H.K. Jensen, E. Casao, F. Civeira, J. González-Bonillo, J.C. Rodríguez-Rey, et al.
Identification of recurrent and novel mutations in the LDL receptor gene in Spanish patients with familial hypercholesterolemia.
Hum Mutat, 11 (1998), pp. 413
[9.]
P. Mozas, A. Cenarro, F. Civeira, S. Castillo, E. Ros, M. Pocovi.
Mutation analysis in 36 unrelated Spanish subjects with familial hypercholesterolemia: Identification of 3 novel mutations in the LDL receptor gene.
Hum Mutat, 15 (2000), pp. 483-484
[10.]
P. Mozas, S. Castillo, D. Tejedor, G. Reyes, R. Alonso, M. Franco, et al.
Molecular characterization of familial hypercholesterolemia in Spain: identification of 39 novel and 77 recurrent mutations in LDLR.
Hum Mutat, 24 (2004), pp. 187
[11.]
L.F. Soria, E.H. Ludwig, H.R. Clarke, G.L. Vega, S.M. Grandy, B.S. Mc Carthy.
Association between a specific apoprotein B mutation and familial defective apoB-100.
Proc Natl Acad Sci USA, 86 (1989), pp. 587-591
[12.]
S. Castillo, D. Tejedor, P. Mozas, G. Reyes, F. Civeira, R. Alonso, et al.
The apolipoprotein B R3.500Q gene mutation in Spanish subject with a clinical diagnosis of familial hypercholesterolemia.
Atherosclerosis, 165 (2002), pp. 127-135
[13.]
S.C. Hunt, P.N. Hopkins, K. Bulka, M.T. McDermott, T.L. Thorne, B.B. Wardell, et al.
Genetic localization to chromosome 1p32 of the third locus for familial hypercholesterolemia in a Utah kindred.
Arterioscler Thromb Vasc Biol, 20 (2000), pp. 1089-1093
[14.]
R. Alonso, S. Castillo, F. Civeira, J. Puzo, J.J. La Cruz, M. Pocovi, et al.
Hipercolesterolemia familiar heterocigota en España. Estudio descriptivo de 819 casos no relacionados.
Med Clin (Barc), 118 (2002), pp. 487-492
[15.]
S. Bertolini, A. Cantafora, M. Averna, C. Cortese, C. Motti, S. Martin, et al.
Clinical expression of familial hypercholesterolemia in clusters of mutations of the LDL receptor gene that cause a receptor-defective or receptor-negative phenotype.
Arterioscler Thromb Vasc Biol, 20 (2000), pp. 41-52
[16.]
O. Descamps, X. Leysen, F. Van Leuven, F.R. Heller.
The use of Achiles tendon ultrasonography for the diagnosis of familial hypercholesterolemia.
Atherosclerosis, 157 (2001), pp. 514-518
[17.]
M.A. Austin, C.M. Hutter, R.L. Zimmern, S.E. Humphries.
Familial hypercholesterolemia and coronary heart disease. A HuGE Association review.
Am J Epidemiol, 160 (2004), pp. 421-429
[18.]
H. Mabuchi, J. Koizumi, M. Shimizu, R. Takeda.
Development of coronary heart disease in familial hypercholesterolemia.
Circulation, 79 (1989), pp. 225-232
[19.]
B. Mouratidis, E.F. Vaughan-Neil, D.L. Gilday, et al.
Detection of silent coronary artery disease in adolescents and young adults with familial hypercholesterolemia by single-photon emission compounded tomography thalium-201 scanning.
Am J Cardiol, 70 (1992), pp. 1109-1112
[20.]
J. Defesche.
Familial hypercholesterolemia.
pp. 65-76
[21.]
H. Schuster, F. Luft.
Clinical criteria versus DNA diagnosis in heterozygous familial hypercholesterolemia. Is molecular diagnosis superior to clinical diagnosis?.
Arterioscler Thromb Vasc Biol, 18 (1998), pp. 331-332
[22.]
WHO. Human Genetic Program. Familial hypercholesterolemia, report of a WHO consultation. WHO/HGN/FH/CONS/ 98.7 Paris: WHO; October 1997.
[23.]
Familial hypercholesterolemia (FH).
Report of a World Health Organization Study group.
Human Genetics Programme, (1998),
[24.]
Scientific Steering Committee on behalf of the Simon Broome Register Group.
Mortality in treated heterozigous familial hypercholesterolemia: implications for clinical management.
Atherosclerosis, 142 (1999), pp. 105-112
[25.]
J.S. Hill, M.R. Hayden, J. Frohlich, P.H. Pritchard.
Genetic and enviromental factors affecting the incidence of coronary artery disease in heterozygous familial hypercholesterolemia.
Arterioscler Thromb, 11 (1991), pp. 290-297
[26.]
S. Nishimura, M. Sekiguchi, T. Kano, S. Ishiwata, F. Nagasaki, T. Nishide, et al.
Effects of intensive lipid lowering by low-density lipoprotein aphaeresis on regression of coronary atherosclerosis in patients with familial hypercholesterolemia: Japan Lowdensity Lipoprotein Apheresis Coronary Atherosclerosis Prospective Study (L-CAPS).
Atherosclerosis, 144 (1999), pp. 409-417
[27.]
A.A. Kroon, W.R. Aengevaeren, T. Van der Werf, G.J. Uijen, J.H. Reiber, A.V. Bruschke, et al.
LDL-Apheresis Atherosclerosis Regression Study (LAARS). Effect of aggresive versus conventional lipid lowering treatment on coronary atherosclerosis.
Circulation, 93 (1996), pp. 1826-1835
[28.]
G.R. Thompson, V.M. Maher, S. Matthews, Y. Kitano, C. Neuwirth, M.B. Shortt, et al.
Familial Hypercholesterolemia Regression Study: a randomised trial of low-density-lipoprotein apheresis.
Lancet, 345 (1995), pp. 811-816
[29.]
M. Matsuzaki, K. Hiramori, T. Imaizuni, A. Kitabatake, H. Hishida, M. Nomura, et al.
Intravascular ultrasound evaluation of coronary plaque regression by low-density-lipoprotein apheresis in familial hypercholesterolemia: the Low Density Lipoprotein-Apheresis Coronary Morphology and Reserve Trial (LACMART).
J Am Coll Cardiol, 40 (2002), pp. 220-227
[30.]
C.E. Pitsavos, K.I. Aggeli, J.D. Barbetseas, I.N. Skoumas, S.G. Lambrou, A.A. Frogoudaki, et al.
Effects of pravastatin on thoracic aortic atherosclerosis in patients with heterozygous familial hypercholesterolemia.
Am J Cardiol, 82 (1998), pp. 1484-1488
[31.]
T.J. Smilde, S. Van Wissen, H. Wollersheim, M.D. Trip, J.J. Kastelein, A.F. Stalenhoef.
Effect of aggressive versus conventional lipid lowering on atherosclerosis progression in familial hypercholesterolemia (ASAP): a prospective, randomised, doubleblind trial.
Lancet, 357 (2001), pp. 577-581
[32.]
R. Alonso, P. Mata, R. De Andrés, B.P. Villacastín, J. Martínez-González, L. Badimon.
Sustained long-term improvement of arterial endothelial function in heterozygous familial hypercholesterolemia patients treated with simvastatin.
Atherosclerosis, 157 (2001), pp. 423-429
[33.]
M. De Lorgeril, S. Renaud, N. Mamelle, P. Salen, J.L. Martin, I. Monjaud, et al.
Mediterranean alpha-linolenic acid-rich diet in secondary prevention of coronary heart disease.
Lancet, 343 (1994), pp. 1454-1459
[34.]
F. Pérez-Jiménez, J. López Miranda, P. Mata.
Protective effect of dietary monosaturated fat on atherosclerosis: beyond cholesterol.
Atherosclerosis, 163 (2002), pp. 385-398
[35.]
W.S. Harris, Y. Park, W. Isley.
Cardiovascular disease and long chain omega-3 fatty acids.
Curr Opin Lipidol, 14 (2003), pp. 9-14
[36.]
A.L. Amundsen, L. Ose, M.S. Nenseter, F. Ntanios.
Plant sterol ester-enriched spread lowers plasma total and LDL cholesterol in children with familial hypercholesterolemia.
Am J Clin Nutr, 76 (2002), pp. 338-344
[37.]
H. Gylling, M.A. Siimes, T.A. Miettinen.
Sitostanol ester margarine in dietary treatment of children with familial hypercholesterolemia.
J Lipid Res, 36 (1995), pp. 1807-1812
[38.]
Executive Summary of The Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA. 2001;285:2486-97.
[39.]
S. De Jongh, L. Ose, T. Szamosi, C. Gagne, M. Lambert, R. Scott, et al.
Efficacy and safety of statin therapy in children with familial hypercholesterolemia. A randomised, double-blinded, placebo-controlled trial with simvastatin.
Circulation, 106 (2002), pp. 2231-2237
[40.]
E.A. Stein, D.R. Illingworth, P.O. Kwiterovich Jr, C.A. Liacouras, M.A. Siimes, M.S. Jacobson, et al.
Efficacy and safety of lovastatin in adolescent males with heterozygous familial hypercholesterolemia: a randomized controlled trial.
JAMA, 281 (1999), pp. 137-144
[41.]
A. Wiegman, B.A. Hutten, E. De Groot, J. Rodenburg, H. Bakker, H. Büller, et al.
Efficacy and safety of statin therapy in children with familial hypercholesterolemia.
JAMA, 292 (2004), pp. 331-337
[43.]
T. Sudhop, D. Lütjohann, A. Kodal, M. Igel, D.L. Tribble, S. Shah, et al.
Inhibition of intestinal cholesterol absorption by ezetimibe in humans.
Circulation, 106 (2002), pp. 1943-1948
[44.]
M.E. Brousseau, E.J. Schaefer, M.L. Wolfe, L.T. Bloedon, A.G. Diganio, R.W. Clark, et al.
Effects of an inhibitor of cholesteryl ester transfer protein on HDL cholesterol.
N Engl J Med, 350 (2004), pp. 1005-1015
[45.]
L.C. Hudgins, B.R. Gordon, T.S. Parker, S.D. Saal, D.M. Levine, A.L. Rubin.
LDL apheresis: an effective and safe treatment for refractory hypercholesterolemia.
Cardiovasc Drug Rec, 20 (2002), pp. 271-280
Copyright © 2005. Sociedad Española de Endocrinología y Nutrición
